The U.S. Food and Drug Administration (FDA) approved six new therapies in December 2025 for blood cancers, prostate cancer, ...

The going has been strong for Regeneron Pharmaceuticals REGN over the past six months. Shares of this biotech giant have ...

Radiation therapy has been a foundation of cancer care for more than a century. From early X-ray machines to today’s ...

Explore innovative treatments for relapsed follicular lymphoma, focusing on novel therapies that enhance patient outcomes and ...

Shared decision-making—balancing clinical data with the patient's personal, logistical, and risk-tolerance factors—is ...

Lunsumio Velo is supplied as a ready-to-use, preservative-free solution in single-dose vials containing 5mg/0.5mL and 45mg/mL.

Incyte recently reported positive topline results from its pivotal Phase 3 frontMIND trial, where adding tafasitamab (Monjuvi/Minjuvi) and lenalidomide to R-CHOP improved progression-free survival for ...

Incyte has reported positive top line data from the pivotal Phase III frontMIND trial assessing the safety and efficacy of ...

Incyte today announced positive topline results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19 ...

The US FDA approved 46 new drugs in 2025, despite a tumultuous year at the regulatory agency.

Based on phase 3 trial data, the FDA accepted an sBLA for nivolumab plus AVD for untreated stage III or IV classical Hodgkin lymphoma.

A study finds that over one-third of frontal fibrosing alopecia cases occur in people with skin of color, who are diagnosed a decade earlier than White patients.